Literature DB >> 10221531

Sequences downstream of the RNA initiation site of the HTLV type I long terminal repeat are sufficient for trans-activation by human cytomegalovirus immediate-early proteins.

J M Kim1, Y Hong, S Kim, M H Cho, M Yoshida, K T Jeang, W Burns, S Kim.   

Abstract

Human T cell leukemia virus type I infection is associated with a low incidence of morbidity in the form of adult T cell leukemia and neurologic disease, suggesting that there are other factors determining the pathogenic outcome of infection. We found that HCMV could infect various human cell lines known to be susceptible to HTLV-I infection, including T cell lines already harboring HTLV-I, and that HCMV infection could highly activate gene expression from the HTLV-I LTR. In addition, the coexpression of IE1 and IE2 genes of HCMV increased transcription from the HTLV-I LTR. The deletion analysis indicated that the entire U3 region is not required, but that the 216-bp region from +101 to +316 is sufficient for activation of the LTR by IE1 and IE2. These results suggest that HCMV IE proteins may affect the level of HTLV-I gene expression in coinfected individuals by interacting with HTLV-I LTR sequences.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10221531     DOI: 10.1089/088922299311060

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  3 in total

1.  Characterization of the elements and proteins responsible for interferon-stimulated gene induction by human cytomegalovirus.

Authors:  Shaojun Yang; James Netterwald; Weijia Wang; Hua Zhu
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Enhancement of enteric adenovirus cultivation by viral transactivator proteins.

Authors:  Misoon Kim; Mi Young Lim; GwangPyo Ko
Journal:  Appl Environ Microbiol       Date:  2010-02-05       Impact factor: 4.792

3.  Human cytomegalovirus IE1 protein elicits a type II interferon-like host cell response that depends on activated STAT1 but not interferon-γ.

Authors:  Theresa Knoblach; Benedikt Grandel; Jana Seiler; Michael Nevels; Christina Paulus
Journal:  PLoS Pathog       Date:  2011-04-14       Impact factor: 6.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.